Weekly injection for obesity without diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a new once-weekly injection called Ribupatide for weight loss in people with obesity who do not have diabetes. It compares the study drug to an existing medication (semaglutide) and a placebo to see how well it works and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your body mass index (BMI) must be 35 or higher.
- You must have tried to lose weight through diet or exercise in the last 6 months without success.
- You cannot have diabetes or a history of diabetes.
- Your weight must have stayed stable (not changed more than 5%) in the last 3 months.
- You cannot have started certain weight-affecting medications (like some antidepressants) in the last 3 months.
- You cannot have a personal or family history of certain thyroid cancers or a condition called multiple endocrine neoplasia type 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-weekly injection (tirzepatide) versus a placebo to help people who are obese or overweight with related health conditions lose weight. You may qualify if you have tried to lose weight through diet before, but have not been successful.
This trial tests a new medication, Ribupatide, to see if it helps people with obesity or overweight who also have weight-related health problems. You cannot have diabetes to join.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.
This study tests an injectable medication called semaglutide to help with weight loss in people with a BMI of 28 or higher who have struggled to lose weight before. It compares the study drug to a similar approved weight loss medicine (Wegovy).
This trial tests if semaglutide (a weekly injection) helps people who lost less weight than expected after gastric bypass or sleeve surgery. It's for patients who had a high BMI before surgery and are in a special support program.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.